ClinicalTrials.gg
Not yet recruitingNCT07839091PEARLUpdated Sep 24, 2026

Comparing Myopia Control Spectacle Lenses and Standard Single Vision Spectacle Lenses in Children With Myopia

An interventional study of Investigational Myopia Control Spectacle Lens and Single Vision Spectacle Lens in Myopia and Myopia Progression, sponsored by Essilor International. Not yet recruiting at 1 site in Singapore. Open to participants aged 6 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Essilor International · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
6 Years to 10 Years
Sex
All
01

Study summary

The purpose of this clinical trial is to compare a new myopia control spectacle lens with a standard single vision spectacle lens in slowing the progression of myopia (nearsightedness) in healthy children aged 6 to under 11 years.

The main question being studied is:

Is the new myopia control spectacle lens more effective than a standard single vision spectacle lens in slowing myopia progression?

In this study, participants will wear a myopia control spectacle lens in one eye and a standard single vision spectacle lens in the other eye for the first 6 months. The lens assignment will then be switched between eyes for the remaining 6 months. Researchers will compare changes in eye axial length and refractive error between the two lens types.

Participants will:

  • Wear the study spectacles for 12 months.
  • Attend scheduled follow-up visits at the Essilor R\&D Centre, Singapore.
02

Conditions studied

  • Myopia
  • Myopia Progression

Keywords

  • refractive error
  • myopia control
  • axial length
03

In context

Myopia

1,159 studies on the registry are indexed under Myopia; 225 are open to participants now.

This study's planned enrollment of 20 is below the median of 78 across 923 interventional studies indexed under Myopia.

Browse Myopia studies →

Lead sponsor

Essilor International is the lead sponsor of 38 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Volunteer participant with the willingness and ability to comply with all scheduled study visits.
  2. of parent/guardian and assent of participant.
  3. Age equal to or greater than 6 years and less than 11 years (before 11th birthday) at the time of consent.
  4. Spherical equivalent refraction (SER) equal or less than -0.50 D and equal or greater than -4.75D with astigmatism not more than 2.00 D.
  5. Difference in SER (anisometropia) between two eyes should not exceed 1.00 D.
  6. Best corrected Distance Visual Acuity (BCDVA) better than or equal to +0.10 LogMAR under high contrast in each eye.
  7. Be in good general health, based on the participant and the parent's/guardian's knowledge.
  8. Agree to wear the study spectacles for 12 hours per day and 7 days per week.
  9. Agree not to be involved in other myopia control treatments.

Exclusion criteria

Exclusion Criteria:

  1. History of Atropine, Orthokeratology, Myopia Control Contact Lens, or Red Light treatment.
  2. Strabismus by cover test at near or distance wearing correction.
  3. History and presence of amblyopia.
  4. Any ocular or systemic condition known to affect refractive status (e.g. keratoconus, diabetes, Downs syndrome, or other developmental disorders, etc.).
  5. Current use of ocular or systemic medications which, in the investigator's opinion, may significantly affect pupil size, accommodation or refractive state.
  6. History of ocular injury or surgery.
  7. Participation in any clinical study within 30 days of the Baseline visit.
  8. Current or anticipated use of growth hormones.
  9. Study participants deemed inappropriate for the study by the investigator.
  10. The inherent ocular/systemic discomfort (dry eyes, visual fatigue, headaches, etc.) that may affect the evaluation of the study lens wearing experience, from the investigator's perspective.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    OD: SVL; OS: MCL then OD: MCL; OS: SVL

    Participants will wear the investigational myopia control spectacle lens in the left eye and a standard single vision spectacle lens in the right eye for the first 6 months. After 6 months, the lens assignment will be switched, with each eye wearing the opposite lens type for another 6 months.

    Device: Investigational Myopia Control Spectacle Lens · Device: Single Vision Spectacle Lens

  • Experimental
    OD: MCL; OS: SVL then OD: SVL; OS: MCL

    Participants will wear the investigational myopia control spectacle lens in the right eye and a standard single vision spectacle lens in the left eye for the first 6 months. After 6 months, the lens assignment will be switched, with each eye wearing the opposite lens type for another 6 months.

    Device: Investigational Myopia Control Spectacle Lens · Device: Single Vision Spectacle Lens

Interventions

  • DeviceInvestigational Myopia Control Spectacle Lens

    A spectacle lens designed to help slow the progression of myopia in children

  • DeviceSingle Vision Spectacle Lens

    A standard spectacle lens used to correct refractive error without a specific myopia control feature

06

What researchers measure

Primary outcomes

  1. Change in Eye Axial Length

    Time frame: From baseline to 6 months

Secondary outcomes

  1. Change in Eye Axial Length

    Time frame: From 6 months to 12 months

  2. Change in Eye Non-Cycloplegic Spherical Equivalent Refraction

    Time frame: From baseline to 6 months

  3. Change in Eye Non-Cycloplegic Spherical Equivalent Refraction

    Time frame: From 6 months to 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07839091
Responsible party
Sponsor
First posted
Sep 24, 2026
Start date
Oct 2026 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Sep 24, 2026

Study contacts

Celine Carimalo
Contact
carimalc@essilor.com.sg
67134617 ext. +65
Thomas Boudenne
Contact
thomas.boudenne@essilor.com
Andrew Tan
principal investigator · Essilor R&D Centre Singapore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion